Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Careers
Citizenship »
« Back
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Careers
Citizenship »
« Back
Investors »
« Back

Aclaris - Investor Relations

Investor Overview
Stock Information
Press Releases
Events
SEC Filings
Corporate Governance
Investor Presentations
Investor FAQs
Email Alerts

Investor Contact

For investor related questions, please email

investors@aclaristx.com

Investor Presentations

Investor Presentations

Aclaris Therapeutics Presents ATI-450 Phase 2b Rheumatoid Arthritis Data

Aclaris Therapeutics Company Overview – November 2023

Aclaris Therapeutics Company Overview – November 2023

Multiple Ascending Dose (MAD) Results of ATI-2138 (Investigational Novel Covalent ITK-JAK3 Inhibitor) – September 2023

Multiple Ascending Dose (MAD) Results of ATI-2138 (Investigational Novel Covalent ITK-JAK3 Inhibitor) – September 2023

Aclaris Therpeutics Q1 2023 Financial Results Presentation

Aclaris Therpeutics Q1 2023 Financial Results Presentation

Aclaris - Footer Menu

Terms of Use
Privacy Policy
Contact Us
Fraudulent Activity Notice

© 2023 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.